Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Begacestat · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Donepezil plus placebo | EXPERIMENTAL | - |
| Donepezil plus begacestat | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Donepezil plus placebo | DRUG | 5- and 10-mg tablets, single dose |
| Donepezil | DRUG | 5- and 10-mg tablets, single dose |
| Begacestat | DRUG | 6 x 50-mg capsules, single dose |
Inclusion Criteria: * Healthy * Men and women of non-childbearing potential * Non smoker or smoker of \<10 cigarettes per day and able to refrain from smoking during study * 18-50 years old Exclusion Criteria: * Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocr...
Begacestat is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It is a gamma-secretase inhibitor that has been studied in Phase 1 clinical development. The specific disease indications for begacestat have not been disclosed, and it is not approved for any use.
Begacestat targets the gamma-secretase complex, specifically the subunits APH1A, APH1B, PSEN1, PSEN2, PSENEN, and NCSTN. It acts as an inhibitor of this complex. Gamma-secretase is involved in cleaving amyloid precursor protein, and inhibiting it reduces amyloid-beta production.
Begacestat is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the sponsor of the clinical trial evaluating the drug.
Begacestat is in Phase 1 clinical development. It has not been approved by the FDA or any regulatory agency. One Phase 1 trial has been completed, and there are currently no active trials of begacestat.
Begacestat has been evaluated in one completed Phase 1 trial, NCT00959881, titled "Study Evaluating The Coadministration of Begacestat And Donepezil." The trial enrolled 47 healthy adult volunteers in the United States and was randomized, double-blind, and controlled.